Join our expert-led webinar on May 14th at 8:30am PST | 11:30am EST | 4:30pm GMT to explore critical challenges in developing and manufacturing antibody-oligonucleotide conjugates (AOCs). These innovative therapies hold transformative potential for previously untreatable diseases, but their complexity requires specialized strategies to ensure success.

Successfully developing AOCs is not straightforward, as significant complexities involving sequence fidelity, conjugation stability and impurity management can hinder progress. Additionally, finding an experienced development partner with proven expertise in protein engineering, oligo chemistry and bioconjugation strategies can be challenging.

In this webinar, join Dr Stephen Verespy, Scientific Leader, and Dr Jeffrey Mocny, Vice President of Regulatory Strategy at Abzena, as they directly address key issues in AOC development. Gain actionable insights and practical strategies to overcome chemistry, technical and regulatory hurdles, helping you achieve greater success in your AOC programs.

Key learning points:

• Explore the unique chemical complexities of integrating antibody and oligonucleotide components into effective, manufacturable AOCs.
• Gain practical insights into oligo synthesis techniques and bioconjugation strategies.
• Understand key differences between AOCs and ADCs, focusing on payload complexity, impurity profiles, and essential analytical methods.
• Navigate the evolving regulatory landscape, including considerations around impurity control, stability, immunogenicity, and defining clear target product profiles.

Register Here

Our Speakers:

Dr Stephen Verespy – Scientific Leader, Abzena

Dr Stephen Verespy earned his PhD in Chemical Biology from Virginia Commonwealth University at the Center for Drug Discovery and completed and completed postdoctoral training in Chemical Glycobiology at the University of California, San Diego. He brings extensive expertise in small molecule organic synthesis, linker design and synthesis, and bioconjugation, specifically focusing on ADCs, glycans, oligonucleotides, and peptide conjugates. Verespy currently serves as Director of the Scientific Office at Abzena, leveraging his substantial experience – including six years at a San Diego-based biotech, where he most recently led bioconjugation and chemistry initiatives.

Dr Jeffrey Mocny – VP of Regulatory Strategy, Abzena
Dr Jeffrey C. Mocny joined Abzena in early 2022 as Scientific Lead for Product Strategy, Regulatory Strategy, Quality Management, and Product Development, based at their Bristol, PA facility. Before joining Abzena, Mocny served as Senior Vice President of Regulatory Affairs at ProEd Regulatory, a medical communications and strategy agency. With over three decades of experience in drug development and regulatory strategy, Mocny has extensive expertise guiding programs from concept to completion across biotechnology, nutraceutical, and pharmaceutical industries.